Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Home
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC); Colorectal Cancer

Interventions: Drug: Spevatamig (PT886); Drug: Paclitaxel; Drug: Gemcitabine; Drug: Abraxane; Drug: KEYTRUDA® (pembrolizumab); Drug: FOLFOX; Drug: CAPOX; Drug: FOLFIRINOX; Drug: TAS 102; Drug: Bevacizumab; Drug: Gemcitabine Combined With Cisplatin; Drug: NALIRIFOX

Sponsors: Phanes Therapeutics; Merck Sharp & Dohme LLC

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 29, 2026ClinicalTrials.govComments OffGastroenterologyClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine

Comments